Kyle Battiston, PhD, Sr Engineer Mgr & Wendy Naimark, PhD, CTO, will be presenting at 2021 CRS Virtual Annual Meeting
2021 CRS Virtual Annual Meeting
TORONTO, CANADA / November 25, 2025 - Ripple Therapeutics Corporation, a clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants, is pleased to announce that, earlier this year, it entered into an evaluation program and licensing option agreement with an affiliate of Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better.
Co-Founder and Chief Technology Officer, Wendy Naimark, PhD., recently presented “Overview of the Epidel Prodrug Engineered Sustained Drug Delivery Platform” at PODD: Partnership Opportunities in Drug Delivery. Click to View
